Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers.
Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura S, Mzannar Y, Azar I, Beal E, Tobon M, Kim S, Beydoun R, Baloglu E, Senapedis W, El-Rayes B, Philip PA, Mohammad RM, Shields AF, Al-Hallak MN, Azmi AS.
Khan HY, et al. Among authors: alkhalili o.
bioRxiv [Preprint]. 2023 Mar 27:2023.03.27.534309. doi: 10.1101/2023.03.27.534309.
bioRxiv. 2023.
PMID: 37034616
Free PMC article.
Updated.
Preprint.